Malignant Pleural Mesothelioma - A Pipeline Analysis Report
- Published: Jun 2018
- Pages: 149
- SKU: IRTNTR22254
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for malignant pleural mesothelioma including molecules at pre-clinical and discovery stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapy, route of administration, and target.
Malignant pleural mesothelioma industry analysis
Malignant pleural mesothelioma is a rare and aggressive cancer that develops in a thin layer of tissue surrounding the lungs known as pleura. MPM is caused by the inhalation of microscopic asbestos fibers. Once the person inhales asbestos dust, the human body struggles to eliminate the needle-like fibers of asbestos from lungs. According to the NIH, the incidences of MPM in Europe is about 20 per million inhabitants, and it is increasing globally. This will subsequently demand the need for the development of innovative treatments for malignant pleural mesothelioma, driving the market’s growth.
Furthermore, according to the CDC, the median survival of MPM patients is approximately one year from the time of diagnosis. Also, the global estimated incidences of MPM is around 2,000-3,000 cases annually, and the number is likely to increase owing to the exposure to asbestos, in turn, will influence the malignant pleural mesothelioma market growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of malignant pleural mesothelioma. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Malignant pleural mesothelioma market value: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development for malignant pleural mesothelioma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Selecta Biosciences
Therapeutic assessment of the drug development for malignant pleural mesothelioma by route of administration
The IV route of administration (ROA) involves the application of the drug directly into a vein.
Therapeutic assessment of the drug development for malignant pleural mesothelioma by therapy
- Combination therapy
Malignant pleural mesothelioma industry analysis, all the molecules in the drug development for malignant pleural mesothelioma are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for malignant pleural mesothelioma?
- What are the companies that are currently involved in the drug development of malignant pleural mesothelioma?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.